Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus Toripalimab in Advanced SCLC
NCT03904719Phase 2Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib in small cell lung cancer (SCLC), sponsored by AnewPharma Company, Ltd. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
vorolanib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03904719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904719.